Kenvue Inc. (KVUE)
Kimberly-Clark to acquire Tylenol-maker Kenvue in $48.7B deal
Kimberly-Clark Corp (NYSE:KMB, ETR:KMY) announced it will acquire Kenvue (NYSE:KVUE), the maker of Tylenol and other consumer health products, in a cash and stock transaction valued at approximately $48.7 billion. Under the agreement, Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, totaling $21.01 per share based on Kimberly-Clark's recent stock price.
Tylenol Maker Eyes Best Day Ever on Kimberly-Clark Deal
Tylenol maker and former Johnson & Johnson (JNJ) spinoff Kenvue Inc (NYSE:KVUE) is 16.7% higher to trade at $16.74, after Kimberly-Clark Corp (NASDAQ:KMB) agreed to purchase the pharma name for $48.70 billion in cash and stock.
Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day.
D.E. Shaw, one of the Tylenol-maker's largest shareholders, stood to lose over $200 million but is now expected to break even on its bet.
Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Deal
This is a developing story.
Kimberly-Clark to buy embattled Tylenol maker Kenvue in a deal valued at more than $48 billion
Kenvue's stock, which had hit a record low in recent weeks, was headed for its best day ever while Kimberly-Clark's stock tumbled.
Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark's $48.7-billion deal
Kenvue missed Wall Street estimates for third-quarter sales on Monday, while it also announced its acquisition by Kimberly-Clark for about $48.7 billion.
Kimberly-Clark agrees to buy Kenvue in $48.7 billion deal, creating consumer staples giant
Kimberly-Clark announced Monday it's struck an agreement to buy Kenvue in a deal valued at $48.7 billion. The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol.
Kimberly-Clark to Buy Kenvue in Deal That Values Tylenol Maker at $48.7 Billion
Kimberly-Clark will buy Kenvue for cash and stock.
Kimberly-Clark to acquire Kenvue in $48.7 billion deal
Kimberly-Clark said on Monday it will acquire Tylenol maker Kenvue in a deal valued at about $48.7 billion.
Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Embattled Tylenol Maker Kenvue Hires New Marketing Chief
The company plans to name snack food executive Jon Halvorson as it faces a crisis over concerns of links between Tylenol and autism.
Texas sued Tylenol maker Kenvue, alleging it deceived pregnant women about risks associated with autism
The suit alleges that the Tylenol maker engaged in deceptive marketing by advertising the product as safe to use while pregnant.
